AYER, Mass.–(BUSINESS WIRE)–Cambrooke Therapeutics, Inc. (“Cambrooke”), a global therapeutic nutrition innovator, is pleased to announce the closing of the Series C investment round, led by Seventure Partners (Paris, France), an asset manager, investing out of its latest healthcare and nutrition focused Health For Life CapitalTM vehicle. Seventure is joined by Cambrooke’s existing main investor, Galen Partners (Stamford, Connecticut), as well as further co-investors from both Europe and the United States.
Cambrooke Therapeutics, Inc. has closed the Series C investment round, led by Paris-based Seventure Partners.
“Seventure Partners invests in North American and European companies with disruptive products and proven leadership teams,” said Seventure President and CEO Isabelle de Cremoux. “In Cambrooke, we see a remarkable mixture of both, and we look forward to building on Cambrooke’s established reputation and continued success in highly specialized nutrition for people with chronic health conditions worldwide.”
Cambrooke’s core Medical Food portfolio is serving the needs of people with phenylketonuria (PKU). The Company’s proprietary Glytactin protein source represents the first significant advance in PKU nutrition since newborn screening for PKU started in the late 1960s. Cambrooke recently expanded its focus to include products for people with other inborn errors of protein metabolism and for people with intractable epilepsy using ketogenic diet therapy. The Company compliments this portfolio with the most complete range of low protein functional foods for inborn errors of metabolism and a growing range of ketogenic diet therapy appropriate functional foods.
“Following Galen’s initial investment in 2011, Cambrooke has grown to offer the most advanced Medical Foods and functional foods for people with inborn errors of metabolism and intractable epilepsy,” said Cambrooke’s CEO Howard Lossing. “This round of financing provides us great strategic value well beyond the capital raised; I look forward to leveraging the expertise of our new investors as we continue our global expansion and entry into other disease states.”
In connection with the investment, Seventure Partners’ Oxana Kukhaneva, venture partner, joins the Board of Directors of the company.
About Cambrooke Therapeutics
Founded in 2000, Cambrooke is a private equity-backed, Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious chronic unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialize products that are today focused on inborn errors of metabolism and intractable epilepsy. More information is available at www.cambrooketherapeutics.com.
About Seventure Partners
With over €600m in assets under management as of the end of 2015, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in digital technologies, in France and Germany, and in the life sciences field across Europe and North America. In life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. For more details: www.seventure.com
About Galen Partners
Galen Partners is a leading health care private equity investment firm based in Stamford, Conn. The firm focuses on growth equity investments in health care technology-enabled services, medical devices and specialty pharmaceutical companies. With nearly $1 billion under management raised through five funds, Galen has invested in more than 70 companies since 1990. The firm continues a tradition of strategic collaboration and partnership with its portfolio company management teams to build health care market leaders. More information is available at www.galen.com.